{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:13:55Z","timestamp":1788984835725,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Almirall S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01840-9","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:09:35Z","timestamp":1782929375000},"page":"4719-4728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week\u00a04 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase\u00a0III Trials"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-6993","authenticated-orcid":false,"given":"Maria","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-6318","authenticated-orcid":false,"given":"Juan Manuel","family":"Mor\u00f3n-Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-2129","authenticated-orcid":false,"given":"Jordi","family":"Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoub","family":"Bentohami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8613-5302","authenticated-orcid":false,"given":"Frank","family":"Freischl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"1840_CR1","doi-asserted-by":"publisher","first-page":"13030\/qt48r4w8h","DOI":"10.5070\/D3208023523","volume":"20","author":"SR Feldman","year":"2014","unstructured":"Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014;20:13030\/qt48r4w8h2.","journal-title":"Dermatol Online J"},{"issue":"Suppl 1","key":"1840_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.18761","volume":"37","author":"A Pinter","year":"2023","unstructured":"Pinter A, van de Kerkhof P. The role of topical therapies along the psoriasis patient journey: an overview from the Symposium \u201cTailoring topical psoriasis treatments to patients\u201d needs and expectations\u2019 of the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023;37(Suppl 1):3\u20138. https:\/\/doi.org\/10.1111\/jdv.18761.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1840_CR3","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s13555-023-01003-0","volume":"13","author":"T Torres","year":"2023","unstructured":"Torres T, Galv\u00e1n J, Crutchley N, et al. Calcipotriol and betamethasone dipropionate cream based on PAD technology for the treatment of plaque psoriasis: a narrative review. Dermatol Ther (Heidelb). 2023;13:2153\u201369. https:\/\/doi.org\/10.1007\/s13555-023-01003-0.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1840_CR4","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s13555-022-00794-y","volume":"12","author":"M Praestegaard","year":"2022","unstructured":"Praestegaard M, Steele F, Crutchley N. Polyaphron dispersion technology, a novel topical formulation and delivery system combining drug penetration, local tolerability and convenience of application. Dermatol Ther (Heidelb). 2022;12:2217\u201331. https:\/\/doi.org\/10.1007\/s13555-022-00794-y.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1840_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/jdv.17734","volume":"36","author":"A Pinter","year":"2022","unstructured":"Pinter A, Green LJ, Selmer J, et al. A pooled analysis of randomized, controlled, phase\u00a03 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36:228\u201336. https:\/\/doi.org\/10.1111\/jdv.17734.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1840_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.36849\/JDD.7372","volume":"22","author":"A Curcio","year":"2023","unstructured":"Curcio A, Kontzias C, Gorodokin B, Feldman S, Kircik L. Patient preferences in topical psoriasis treatment. J Drugs Dermatol. 2023;22:326\u201332. https:\/\/doi.org\/10.36849\/JDD.7372.","journal-title":"J Drugs Dermatol"},{"key":"1840_CR7","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871\u2013881.e1-30. https:\/\/doi.org\/10.1016\/j.jaad.2013.12.018.","journal-title":"J Am Acad Dermatol"},{"key":"1840_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/24755303241290495","volume":"10","author":"A Armstrong","year":"2025","unstructured":"Armstrong A, Levit NA, Schneider B, et al. Patient-identified treatment goals for psoriatic disease: results from a US patient survey. J Psoriasis Psoriatic Arthritis. 2025;10:11\u201321. https:\/\/doi.org\/10.1177\/24755303241290495.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"1840_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamadermatol.2014.3513","volume":"151","author":"VL Pascoe","year":"2015","unstructured":"Pascoe VL, Enamandram M, Corey KC, et al. Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015;151:375\u201381. https:\/\/doi.org\/10.1001\/jamadermatol.2014.3513.","journal-title":"JAMA Dermatol"},{"key":"1840_CR10","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s11136-013-0384-y","volume":"22","author":"JC Cappelleri","year":"2013","unstructured":"Cappelleri JC, Bushmakin AG, Harness J, Mamolo C. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. Qual Life Res. 2013;22:2489\u201399. https:\/\/doi.org\/10.1007\/s11136-013-0384-y.","journal-title":"Qual Life Res"},{"key":"1840_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40257-019-00496-w","volume":"21","author":"LM Perez-Chada","year":"2020","unstructured":"Perez-Chada LM, Salame NF, Ford AR, et al. Investigator and patient global assessment measures for psoriasis clinical trials: a systematic review on measurement properties from the International Dermatology Outcome Measures (IDEOM) initiative. Am J Clin Dermatol. 2020;21:323\u201338. https:\/\/doi.org\/10.1007\/s40257-019-00496-w.","journal-title":"Am J Clin Dermatol"},{"key":"1840_CR12","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1111\/jdv.19330","volume":"37","author":"A Pinter","year":"2023","unstructured":"Pinter A, Reich A, Arenberger P, et al. Randomized phase\u00a03 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2023;37:2327\u201335. https:\/\/doi.org\/10.1111\/jdv.19330.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1840_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.36849\/JDD.2021.5653","volume":"20","author":"L Stein Gold","year":"2021","unstructured":"Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A phase\u00a03, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20:420\u20135. https:\/\/doi.org\/10.36849\/JDD.2021.5653.","journal-title":"J Drugs Dermatol"},{"key":"1840_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","volume":"66","author":"A Robinson","year":"2012","unstructured":"Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66:369\u201375. https:\/\/doi.org\/10.1016\/j.jaad.2011.01.022.","journal-title":"J Am Acad Dermatol"},{"key":"1840_CR15","doi-asserted-by":"publisher","first-page":"e027535","DOI":"10.1136\/bmjopen-2018-027535","volume":"9","author":"B Strober","year":"2019","unstructured":"Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9:e027535. https:\/\/doi.org\/10.1136\/bmjopen-2018-027535.","journal-title":"BMJ Open"},{"key":"1840_CR16","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","volume":"182","author":"SK Mahil","year":"2020","unstructured":"Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182:1158\u201366. https:\/\/doi.org\/10.1111\/bjd.18333.","journal-title":"Br J Dermatol"},{"key":"1840_CR17","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1007\/s12325-022-02124-2","volume":"39","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Edson-Heredia E, Zhu B, et al. Treatment goals for psoriasis as measured by Patient Benefit Index: results of a National Psoriasis Foundation Survey. Adv Ther. 2022;39:2657\u201367. https:\/\/doi.org\/10.1007\/s12325-022-02124-2.","journal-title":"Adv Ther"},{"key":"1840_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamadermatol.2023.2008","volume":"159","author":"V Long","year":"2023","unstructured":"Long V, Chen Z, Du R, et al. Understanding discordant perceptions of disease severity between physicians and patients with eczema and psoriasis using structural equation modeling. JAMA Dermatol. 2023;159:811\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2023.2008.","journal-title":"JAMA Dermatol"},{"key":"1840_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/PTT.S519420","volume":"15","author":"M Ponikowska","year":"2025","unstructured":"Ponikowska M, Vellone E, Czapla M, Uchmanowicz I. Challenges psoriasis and its impact on quality of life: challenges in treatment and management. Psoriasis (Auckl). 2025;15:175\u201383. https:\/\/doi.org\/10.2147\/PTT.S519420.","journal-title":"Psoriasis (Auckl)"},{"key":"1840_CR20","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1080\/09546634.2021.1961996","volume":"33","author":"CEE Choi","year":"2022","unstructured":"Choi CEE, Yee MYF, Tan LYL, Phan P. A qualitative study of dermatology patients and providers to understand discordant perceptions of symptom burden and disease severity. J Dermatol Treat. 2022;33:2344\u201351. https:\/\/doi.org\/10.1080\/09546634.2021.1961996.","journal-title":"J Dermatol Treat"},{"key":"1840_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejim.2022.11.010","volume":"109","author":"V Long","year":"2023","unstructured":"Long V, Lau XMN, Ng CX, Phan P, Choi CEE. Discordance in perception of disease severity between patient and physicians. Eur J Intern Med. 2023;109:138\u201340. https:\/\/doi.org\/10.1016\/j.ejim.2022.11.010.","journal-title":"Eur J Intern Med"},{"key":"1840_CR22","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.3346\/jkms.2018.33.e214","volume":"33","author":"H Kim","year":"2018","unstructured":"Kim H, Lee S, Kim J. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33:e214.","journal-title":"J Korean Med Sci"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01840-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01840-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01840-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:16Z","timestamp":1788981676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01840-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1840"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01840-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Maria Esposito declares to have served as speaker or board member for Abbvie, Almirall, Amgen, BMS, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi-Regeneron, UCB. Juan Manuel Mor\u00f3n-Oca\u00f1a declares no conflicts of interest. Aditya Gupta is a consultant for Almirall S.A. Jordi Galv\u00e1n and Ayoub Bentohami are employees of Almirall S.A. Frank Freischl\u00e4ger is co-founder and co-owner of Estimondo GmbH.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocols of the two phase\u00a0III studies were reviewed and approved by ethics committees or local institutional review boards (independent ethics committee for trial MC2-01-C7: Ethikkommission der \u00c4rztekammer, Hamburg, Weidestra\u00dfe 122b, 22083 Hamburg, Germany; central institutional review board for trial MC2-01-C2: Quorum, 1501 Fourth Ave, Ste 800, Seattle, WA 98101). Both studies were conducted according to the 1964 Declaration of Helsinki and its subsequent amendments. All patients provided written informed consent\u00a0to participate in the phase\u00a0III studies.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}